Holen Sie sich die Stockscreener-App
23.16
0.17%
0.06
Schlusskurs vom Vortag:
$23.10
Offen:
$22.98
24-Stunden-Volumen:
70,710
Relative Volume:
0.08
Marktkapitalisierung:
$1.55B
Einnahmen:
$13.05M
Nettoeinkommen (Verlust:
$-60.54M
KGV:
-19.97
EPS:
-1.16
Netto-Cashflow:
$-37.82M
1W Leistung:
-0.90%
1M Leistung:
-2.77%
6M Leistung:
-56.78%
1J Leistung:
-44.53%
1-Tages-Spanne:
$22.74
$23.45
1-Wochen-Bereich:
$22.55
$24.25
52-Wochen-Spanne:
$22.48
$71.71
Janux Therapeutics Inc Stock (JANX) Company Profile
Firmenname
Janux Therapeutics Inc
Sektor
Branche
Telefon
(858) 751-4493
Adresse
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Vergleichen Sie JANX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
23.19 | 1.55B | 13.05M | -60.54M | -37.82M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
446.58 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
526.35 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.28 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
562.50 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
240.30 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-03 | Bestätigt | BTIG Research | Buy |
| 2024-12-03 | Bestätigt | H.C. Wainwright | Buy |
| 2024-11-22 | Eingeleitet | Leerink Partners | Outperform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-09-06 | Eingeleitet | Stifel | Buy |
| 2024-05-30 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-03-21 | Eingeleitet | BTIG Research | Buy |
| 2024-03-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-04-06 | Eingeleitet | Wedbush | Outperform |
| 2022-11-14 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Janux Therapeutics Inc Aktie (JANX) Neueste Nachrichten
Janux Therapeutics Becomes Oversold (JANX) - Nasdaq
Closing Figures Unveiled: Janux Therapeutics Inc (JANX) Drop -5.18, Closes at 23.61 - DWinneX
Janux Therapeutics, Inc. (JANX) Stock Analysis: Biotechnology Pioneer with 256.30% Potential Upside - DirectorsTalk Interviews
Where are the Opportunities in (JANX) - news.stocktradersdaily.com
Janux Therapeutics reports annual meeting results By Investing.com - Investing.com South Africa
Janux Therapeutics Holds 2025 Annual Stockholders Meeting - TipRanks
Janux Therapeutics reports annual meeting results - Investing.com
Advanced Renal Cell Carcinoma Pipeline 2025: In-depth Clinical - openPR.com
Equities Analysts Issue Forecasts for JANX FY2026 Earnings - Defense World
California State Teachers Retirement System Grows Stock Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
Janux Therapeutics (NASDAQ:JANX) Shares Up 7.9% – Time to Buy? - Defense World
Janux Therapeutics, Inc. (NASDAQ:JANX) Short Interest Update - Defense World
Janux Therapeutics: Advancing Tumor-Targeted Immunotherapy with Innovative T Cell Platform - majiroxnews.com
Janux Therapeutics, Inc. (NASDAQ:JANX) Position Lifted by Ameriprise Financial Inc. - Defense World
SA Asks: Which oncology companies are attractive M&A targets? - Seeking Alpha
Nuveen Asset Management LLC Sells 39,145 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
Millennium Management LLC Invests $6.22 Million in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
BNP Paribas Financial Markets Purchases New Position in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
When the Price of (JANX) Talks, People Listen - news.stocktradersdaily.com
Janux Therapeutics, Inc. (NASDAQ:JANX) Given Average Rating of “Buy” by Analysts - Defense World
How Vir Bio CEO Marianne De Backer Is Rebuilding Commercial Momentum - insights.citeline.com
How Vir CEO Marianne De Backer Is Rebuilding Commercial Momentum - insights.citeline.com
Janux appoints Janeen Doyle chief corporate, business development officer - TipRanks
Janux Therapeutics (JANX) Welcomes New Chief Corporate and Busin - GuruFocus
Janux Therapeutics (JANX) Welcomes New Chief Corporate and Business Development Officer | JANX Stock News - GuruFocus
Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer - Bluefield Daily Telegraph
Northern Trust Corp Buys 42,302 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
Cantor Fitzgerald Brokers Raise Earnings Estimates for JANX - Defense World
Q2 EPS Estimate for Janux Therapeutics Boosted by Analyst - Defense World
Janux Therapeutics Reports Increased Q1 Losses Amid R&D Expansion - TipRanks
Trend Tracker for (JANX) - news.stocktradersdaily.com
Leerink cuts Janux Therapeutics price target to $89, keeps Outperform By Investing.com - Investing.com India
Janux Therapeutics Inc (JANX) Gets a Hold from Scotiabank - The Globe and Mail
Promising Pipeline and Strategic Advancements Justify Buy Rating for Janux Therapeutics Inc - TipRanks
Janux Therapeutics price target lowered to $36 from $41 at Scotiabank - TipRanks
Janux Therapeutics (JANX) Reports Q1 EPS Loss, Maintains Strong Cash Position - GuruFocus
Scotiabank Adjusts Janux Therapeutics (JANX) Price Target Amid T - GuruFocus
Positive Buy Rating for Janux Therapeutics Inc. Driven by Promising Clinical Data and Strong Financial Position - TipRanks
Decoding Janux Therapeutics Inc (JANX): A Strategic SWOT Insight - GuruFocus
Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights - BioSpace
Janux Therapeutics Inc: Undervalued Growth Potential Amid Recent Stock Pullback - TipRanks
Janux Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Janux Therapeutics (JANX) Advances Clinical Trials for JANX007 | JANX Stock News - GuruFocus
Janux Therapeutics reports Q1 EPS (38c), consensus (39c) - TipRanks
BRIEF-Janux Therapeutics Q1 Basic EPS USD -0.38 - TradingView
Buy Rating for Janux Therapeutics Inc. Driven by Strategic Advancements in Prostate Cancer Treatment with JANX007 - TipRanks
Janux Therapeutics (NASDAQ:JANX) Shares Gap Down After Insider Selling - Defense World
Buy Rating for Janux Therapeutics Inc: Promising PFS Data and Attractive Valuation - TipRanks
Janux commences Phase Ib studies in trial for prostate cancer treatment - Clinical Trials Arena
Buy Rating for Janux Therapeutics Inc: Promising Clinical Trial Results and Positive Outlook for JANX007 - TipRanks
Janux Therapeutics Inc expected to post a loss of 39 cents a shareEarnings Preview - TradingView
Finanzdaten der Janux Therapeutics Inc-Aktie (JANX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Janux Therapeutics Inc-Aktie (JANX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Meyer Andrew Hollman | Chief Business Officer |
May 01 '25 |
Sale |
32.03 |
3,333 |
106,745 |
82,139 |
0.27%
0.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):